The value of metastatic screening in early primary breast cancer

Irish Journal of Medical Science

Volumn 168, Issue 4, 1999, Pages 248-250

  Barry, M C ^a   Thornton, F ^b   Murphy, M ^b   Younis, F ^a   Watson, R G K ^a  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ABDOMEN; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; BREAST CANCER; CANCER SCREENING; CANCER STAGING; CARCINOMATOSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIVER FUNCTION TEST; LYMPHANGITIS; MAJOR CLINICAL STUDY; METASTASIS; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 0033384590     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02944350     Document Type: Article

References (24)

1. Gerber, F. H., Goodreau, J. J., Kirchner, P. T., Fouty, W. J. Efficacy of preoperative and postoperative bone scanning in the management of breast carcinoma. NEJM 1977; 297: 300-303.
2. Glynne-Jones, R., Young, T., Ahmed, A., Ell, P. J., Berry, R. J. How far investigation for occult metastases in breast cancer aid the clinician. Clinical Oncology 1991; 3: 65-72.
3. . Scanion, E. F., Oviedo, M. A., Cunningham, M. P., Caprini, J., Khandekar, J. D., Cohen, E., Robinson, B., Stein, E. Preoperative and follow-up procedures on patients with breast cancer. Cancer 1980; 46: 977-9.
4. Forrest, A. P., Stewart, H. J., Everington, D., Prescott, R. J., McArdle, C. S., Harnett, A. N., Smith, D. C., Geroge, W. D. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet 1996; 348: 708-13.
5. Berman, C. G., Clark, R. A. Diagnostic imaging in cancer. Primary Care 1992; 19: 677-713.
6. Hadley, D., Fowble, B., Torosian, M. H. Evidence of selective use of bone scans in early stage breast cancer. Oncol. Rep. 1998,5:991-3.
7. Brar, H. S., Sisley, L F., Johnson, R. H. Value of preoperative bone and liver scans and alkaline phosphatase in the evaluation of breast cancer patients. Am. J. Surg. 1993; 165: 221-223.
8. Anonymous. Consensus Development Conference: treatment of primary breast cancer. Br. Med. J. 1986; 293: 946-7.
9. Galasko, C. S. B. The detection of skeletal metastases from carcinoma of the breast. Surg. Gynecol. Obstet. 1971; 132: 1019-24.
10. Gilbert, H. A., Kagan, A. R. Metastases: incidence, detection and evaluation without histologic confirmation. Fundamental aspects of metastasis. ed Weiss: p. 385-405. North-Holland, Amsterdam.
11. McGarrity, T. J., Samuels, T. N., Wilson, F. A. An analysis of imaging studies and liver function tests to detect hepatic neoplasia. Dig. Dis. Sci. 1987; 32: 1113-7.
12. White, D. R., Maloney, III, J. J. et al. Serum alkaline phosphatase determination value in the staging of advanced breast cancer. JAMA 1979; 242: 1147-9.
13. O'Brien, D. P., Horgan, P. G., Gough, D. B., Skehill, R., Grimes, H., Given, H. F. CA 15-3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann. Roy. Coll. Surg. Engl. 1992; 74:9-12.
14. O'Hanlon, D. M., Kerin, M. J., Kent, P. J., Skehill, R., Maher, D., Grimes, H., Given, H. F. A prospective evaluation of CA 15-3 in stage I carcinoma of the breast. J. Am. Coll. Surg. 1995; 180: 210-2.
15. Coveney, E. C., Geraghty, J. G., Sherry, F., McDermott, E. W., Fennelly, J. J., O'Higgins, N. J., Duffy, M. J. The clinical value of CEA and CA 15-3 in breast cancer management. Int. J. Biol. Markers 1995; 10: 35-41.
16. Geraghty, J. G., Coveney, E. C., Sherry, F., O'Higgins, N. J., Duffy, M. J. CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992; 70: 28314.
17. lacopetta, B., Grieu, F., Powell, B., Soong, R., McCaul, K., Seshadri, R. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin. Cancer Res. 1998; 4: 1597-602.
18. Miller, W. R., Elli, I. O., Sinsbury, J. R. C., Dixon, J. M. Prognostic Factors. ABC of breast diseases. BMJ 1994; 309: 1573-76.
19. Duffy, M. J., Duggan, C., Mulcahy, H. E., McDermott, E. W., O'Higgins, N. J. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin. Chem. 1998; 44: 1177-83.
20. Nikolic-Vukosavljevic, D., Grujic-Adanja, G,. NasticMiric, D., Brankovic-Magic, M., Jovanovic, D., Polie, D., Mitrovic, L. Cathepsin D: association between TN-stage and steroid receptor status of breast carcinoma. Tumour Biol. 1998; 19: 329-34.
21. Morgan, P. G., Byrne, J., O'Donoghue, J., Mooney, E., Grimes, H., Given, H. F. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer. Ir. J. Med. Sci. 1997; 166:215-216.
22. Ciatto, S., Pacini, P., Azzini, V., Neri, A. et al. Preoperative staging of primary breast cancer. A Multicentre study. Cancer 1988; 61: 1038-40.
23. Gasparini, G., Toi, M., Verderio, P., Ranieri, G., Dante, S., Bonoldi, E., Boracchi, P., Fanelli, M., Tominaga, T. Prognostic significance of P53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int. J. Oncol. 1998; 12: 1117-25
24. Carlson, R. W., Goldstein, L. J., Gradishar, W. J., Lichter, A. S., McCormick, B., Moe, R. E., Theriault, R. L. Update of the NCCN guidelines for treatment of breast cancer. Oncology 1997; 11: 199-220.